Key points are not available for this paper at this time.
In conclusion, these three biomarkers await validation in a larger patient cohort and could be easily used in future routine diagnostics to predict the outcome of ipilimumab/nivolumab combination therapy in mucosal melanoma patients.
Freiberger et al. (2022) studied this question.